Skip to content

GlaxoSmithKline PLC ADR Price, Chart & Factor Analysis

Free Data & Analytics Access

Latest earnings: April 29, 2026 results vs estimates

GlaxoSmithKline PLC ADR · E.GSK.NYSE · United States
Use symbol E.GSK.NYSE in our API & Excel add-in to retrieve this data ↓
48.68
(0.00%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend -25%
Bubble Risk LOW
Realised Volatility (20D) 27.41%

GlaxoSmithKline PLC ADR Forecast

GlaxoSmithKline PLC ADR short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is negative (3 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 27.4% a year, a typical one-standard-deviation range is 46.80–50.56 over a week, 44.83–52.53 over a month and 35.34–62.02 over a year. (Signals as of 1 Nov 2026.)

GlaxoSmithKline PLC ADR Price Chart

MacroFinance.ai

GlaxoSmithKline PLC ADR Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
GlaxoSmithKline PLC ADR
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
GlaxoSmithKline PLC ADR
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
GlaxoSmithKline PLC ADR
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for GlaxoSmithKline PLC ADR, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on GlaxoSmithKline PLC ADR

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

GlaxoSmithKline PLC ADR Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to GlaxoSmithKline PLC ADR; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

About GlaxoSmithKline PLC ADR (United States)

GlaxoSmithKline PLC ADR is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on GlaxoSmithKline PLC

Frequently asked questions

What is GlaxoSmithKline PLC ADR?
GlaxoSmithKline PLC ADR is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the trading strategies that hold it and free historical data.
What is the latest GlaxoSmithKline PLC ADR price?
The latest close is 48.68 (1 Nov 2026), -0.00% on the day. The price at the top of the page refreshes during the trading day.
Is GlaxoSmithKline PLC ADR in an uptrend?
As of 1 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is negative (3 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is GlaxoSmithKline PLC ADR?
20-day realised volatility is 27.4% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 7.9% over a month and 3.9% over a week.
What factors affect GlaxoSmithKline PLC ADR?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to GlaxoSmithKline PLC ADR, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade GlaxoSmithKline PLC ADR?
58 backtested tactical asset allocation strategies trade GlaxoSmithKline PLC ADR through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
Where can I download free GlaxoSmithKline PLC ADR historical data?
In the Free historical data section of this page: the last 10 years of GlaxoSmithKline PLC ADR daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free GlaxoSmithKline PLC ADR historical data (last 10 years)

Browse or instantly download the last 10 years of GlaxoSmithKline PLC ADR daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.GSK.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2047.76
2026-11-1947.82
2026-11-1848.58
2026-11-1749.24
2026-11-1650.41
2026-11-1350.45
2026-11-1250.188
2026-11-1150.1484
2026-11-1050.7727
2026-11-0951.08
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.